: Leber's hereditary optic neuropathy (LHON) is a rare inherited mitochondrial disease caused by variants in mitochondrial DNA (mtDNA) transmitted exclusively through the maternal line. The disease predominantly affects young males and is characterized by progressive bilateral vision loss. Idebenone, a well-studied drug, modestly enhances the mitochondrial function and visual acuity in many patients with LHON. In this study, we report the case of a 48-year-old woman diagnosed with LHON (m.11778G>A/MT-ND4) and type 2 diabetes mellitus who experienced visual field improvement following metformin treatment after 26 months of progressive vision loss unresponsive to idebenone, nicotinamide adenine dinucleotide (NAD+), and hormone replacement therapy (HRT). Our findings offer an intriguing perspective on LHON management but require more investigations, particularly on the molecular effects of metformin on the mitochondrial function in LHON patients.

Elmaseh, S.A., Gauthier, D.A., Golmohammadi, M., Pargalava, N., Carelli, V., Sadun, A.A. (2025). Metformin may alter the course of Leber's hereditary optic neuropathy: a case report. FRONTIERS IN MEDICINE, 12, 1-13 [10.3389/fmed.2025.1609941].

Metformin may alter the course of Leber's hereditary optic neuropathy: a case report

Carelli, Valerio;
2025

Abstract

: Leber's hereditary optic neuropathy (LHON) is a rare inherited mitochondrial disease caused by variants in mitochondrial DNA (mtDNA) transmitted exclusively through the maternal line. The disease predominantly affects young males and is characterized by progressive bilateral vision loss. Idebenone, a well-studied drug, modestly enhances the mitochondrial function and visual acuity in many patients with LHON. In this study, we report the case of a 48-year-old woman diagnosed with LHON (m.11778G>A/MT-ND4) and type 2 diabetes mellitus who experienced visual field improvement following metformin treatment after 26 months of progressive vision loss unresponsive to idebenone, nicotinamide adenine dinucleotide (NAD+), and hormone replacement therapy (HRT). Our findings offer an intriguing perspective on LHON management but require more investigations, particularly on the molecular effects of metformin on the mitochondrial function in LHON patients.
2025
Elmaseh, S.A., Gauthier, D.A., Golmohammadi, M., Pargalava, N., Carelli, V., Sadun, A.A. (2025). Metformin may alter the course of Leber's hereditary optic neuropathy: a case report. FRONTIERS IN MEDICINE, 12, 1-13 [10.3389/fmed.2025.1609941].
Elmaseh, Shenoda Abd; Gauthier, Danielle A; Golmohammadi, Maryam; Pargalava, Nutsa; Carelli, Valerio; Sadun, Alfredo A
File in questo prodotto:
File Dimensione Formato  
fmed-12-1609941_compressed.pdf

accesso aperto

Tipo: Versione (PDF) editoriale / Version Of Record
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.57 MB
Formato Adobe PDF
1.57 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1035692
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact